<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03824405</url>
  </required_header>
  <id_info>
    <org_study_id>BTX.2018.003</org_study_id>
    <nct_id>NCT03824405</nct_id>
  </id_info>
  <brief_title>Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis</brief_title>
  <official_title>A Randomized, Double-Blind, Vehicle-Controlled Study of the Safety, Tolerability and Efficacy of BTX 1204 in Patients With Moderate Atopic Dermatitis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Botanix Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Botanix Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with&#xD;
      moderate AD.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, double-blind, vehicle-controlled, Phase 2 study in subjects with&#xD;
      moderate AD. Eligible subjects will be enrolled and randomized to treatment with BTX 1204 or&#xD;
      Vehicle for 84 days. Approximately two hundred (200) subjects will be enrolled. Subjects will&#xD;
      receive BID application of study drug for 84 days with a final application on the evening of&#xD;
      Day 84 for a total of 168 doses.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 4, 2019</start_date>
  <completion_date type="Actual">March 4, 2020</completion_date>
  <primary_completion_date type="Actual">January 27, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Investigator's Global Assessment (IGA)</measure>
    <time_frame>Day 85</time_frame>
    <description>Investigator's Global Assessment (IGA) success defined as an IGA score of &quot;Clear&quot; (0) or &quot;Almost Clear&quot; (1) with at least a 2-grade improvement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Signs of Atopic Dermatitis</measure>
    <time_frame>Day 85</time_frame>
    <description>The change from Baseline to Day 85 in the Signs of Atopic Dermatitis score. Signs of atopic dermatitis scale. Total score from 0 to 15 is reported. Signs of atopic dermatitis are assessed on a 4-point scale from non (0) to severe (3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Body Surface Area</measure>
    <time_frame>Day 85</time_frame>
    <description>The change from Baseline to Day 85 in the percent of body surface area (BSA) affected by AD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Itch-Numerical Rating Scale</measure>
    <time_frame>Day 85</time_frame>
    <description>The change from Baseline to Day 85 in the Itch-Numerical Rating Scale (I-NRS). A scale from 0 to 10, where 0 is No itch and 10 is Worst itch imaginable. How would you rate your AVERAGE itch in the past 24 hours?</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From time of consent through Day 85</time_frame>
    <description>Number of subjects reporting treatment-emergent adverse events (TEAE)</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>BTX 1204</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>BTX 1204 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Vehicle twice daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BTX 1204</intervention_name>
    <description>BTX 1204 liquid formulation</description>
    <arm_group_label>BTX 1204</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <description>Vehicle liquid formulation</description>
    <arm_group_label>Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subject is of either gender between 12 and 70 years of age, inclusive.&#xD;
&#xD;
          2. Subject (or parent/legal guardian) has the ability and willingness to sign a written&#xD;
             informed consent.&#xD;
&#xD;
          3. Subject has a diagnosis of chronic (≥1 year), stable atopic dermatitis (AD)&#xD;
&#xD;
          4. Subject has ≥ 5% and ≤ 30% body surface area (BSA) of AD involvement excluding the&#xD;
             scalp and groin.&#xD;
&#xD;
          5. Subject has an Investigator's Global Assessment (IGA) score of moderate (3) atopic&#xD;
             dermatitis on the 5-point IGA (0-4) scale.&#xD;
&#xD;
          6. For selected photography sites, subject has a target lesion of 25 to 200 cm2 in&#xD;
             surface area on the trunk, upper extremities or lower extremities with a Baseline&#xD;
             Signs of AD score of ≥ 6 and ≤ 12.&#xD;
&#xD;
          7. Subject is in good general health without clinically significant hematological,&#xD;
             cardiac, respiratory, renal, endocrine, gastrointestinal, psychiatric, hepatic, or&#xD;
             malignant disease, as determined by the investigator.&#xD;
&#xD;
          8. Subject has suitable venous access for blood sampling.&#xD;
&#xD;
          9. Subject is able and willing to complete the study and to comply with all study&#xD;
             instructions and attend the necessary visits.&#xD;
&#xD;
         10. Male subjects and their partners must agree and commit to use a barrier method of&#xD;
             contraception throughout the study and for 90 days after last study drug application.&#xD;
&#xD;
         11. A negative urine pregnancy test result for all Women of child bearing potential&#xD;
             (WOCBP) at the Screening Visit and Baseline Visit.&#xD;
&#xD;
         12. Sexually active women must agree to use the following throughout the study and for 30&#xD;
             days after last study drug application. WOCBP who are not sexually active at Baseline&#xD;
             and become sexually active must identify a plan for contraception.&#xD;
&#xD;
               1. One of these highly effective contraception methods Intrauterine device (IUD);&#xD;
                  hormonal (injections, implants, transdermal patch, vaginal ring); tubal ligation;&#xD;
                  partner vasectomy, OR&#xD;
&#xD;
               2. Oral contraceptives WITH a barrier method (listed below), OR&#xD;
&#xD;
               3. Two barrier forms of contraception (listed below) Male or female condom;&#xD;
                  diaphragm; cervical cap; contraceptive sponge.&#xD;
&#xD;
         13. Males subjects must refrain from sperm donation during the study treatment period and&#xD;
             until 90 days after last study drug application.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Female subject who is breast feeding, pregnant, or planning to become pregnant.&#xD;
&#xD;
          2. Subject who has an IGA score of 2 (mild) or 4 (severe).&#xD;
&#xD;
          3. Subject with history of known or suspected intolerance to the drug product excipients.&#xD;
&#xD;
          4. Subject has any clinically significant active infection in the investigator's opinion.&#xD;
             This includes active impetigo at any AD lesion.&#xD;
&#xD;
          5. Subject has known Hepatitis-B, Hepatitis-C, or HIV infection.&#xD;
&#xD;
          6. Subject has excessive body or facial hair that would interfere with the evaluation of&#xD;
             safety or with the diagnosis or assessment of AD.&#xD;
&#xD;
          7. Subject has sunburns, unevenness in skin tones, tattoos, scars, excessive hair,&#xD;
             freckles, birthmarks, moles, or other skin damage or abnormality that would result in&#xD;
             the inability to evaluate the AD lesions.&#xD;
&#xD;
          8. Subject has clinically significant or severe allergies that in the investigator's&#xD;
             opinion would interfere with participation in the study.&#xD;
&#xD;
          9. Subject has known intolerability to topical treatments e.g., reports excessive&#xD;
             burning/stinging or pain with use of topical treatments.&#xD;
&#xD;
         10. Subject has an active or potentially recurring skin conditions(s) other than AD that&#xD;
             in the investigator's opinion would interfere with participation in the study.&#xD;
&#xD;
         11. Subject has unstable AD consistent with a requirement for high-potency&#xD;
             corticosteroids.&#xD;
&#xD;
         12. Subject has used dupilumab (Dupixent) within 12 weeks prior to the Baseline Visit.&#xD;
&#xD;
         13. Subject has used any biologic therapy, other than dupilumab, within 28 days prior to&#xD;
             the Baseline Visit.&#xD;
&#xD;
         14. Subject has used systemic (oral, IV or IM) corticosteroids within 28 days prior to the&#xD;
             Baseline Visit. Intra-articular injection for arthroses allowed.&#xD;
&#xD;
         15. Subject has used topical anti-pruritics (e.g., PDE4 inhibitors) within 28 days prior&#xD;
             to the Baseline Visit.&#xD;
&#xD;
         16. If subject is taking oral antihistamines, subject has not been on a stable dose of&#xD;
             oral antihistamines within 28 days prior to the Baseline visit.&#xD;
&#xD;
         17. Subject has used phototherapy, tanning beds, or any other artificial light device&#xD;
             within 28 days prior to the Baseline Visit.&#xD;
&#xD;
         18. Subject has used topical corticosteroids within 14 days prior to the Baseline Visit.&#xD;
&#xD;
         19. Subject has used topical calcineurin inhibitors within 14 days prior to the Baseline&#xD;
             Visit.&#xD;
&#xD;
         20. Subjects has used barrier creams (e.g., Mimyx, Atopiclair), within 7 days prior to the&#xD;
             Baseline Visit.&#xD;
&#xD;
         21. Subject has an underlying disease that requires the use of interfering topical or&#xD;
             systemic therapy.&#xD;
&#xD;
         22. Subject has other dermatological conditions that require the use of interfering&#xD;
             topical or systemic therapy or that might interfere with study assessments such as,&#xD;
             but not limited to, acne or rosacea.&#xD;
&#xD;
         23. Subject has a clinically relevant history or currently suffering from any disease or&#xD;
             condition that, in the opinion of the investigator, may affect the evaluation of the&#xD;
             study product or place the subject at undue risk or interfere with the subject's&#xD;
             participation in the study. Subjects with other dermatologic conditions, including&#xD;
             genetic syndromes that have an eczematous dermatitis as a component of the disease&#xD;
             (e.g., Netherton's) are excluded.&#xD;
&#xD;
         24. Subject has a clinically relevant history of or current evidence of abuse of alcohol&#xD;
             or other drugs.&#xD;
&#xD;
         25. Subject is currently using any medication that, in the opinion of the investigator,&#xD;
             may affect the evaluation of the study product or place the subject at undue risk.&#xD;
&#xD;
         26. Subject has participated in another investigational drug or device research study&#xD;
             within 30 days of the Screening Visit or five half-lives of the drug, whichever is&#xD;
             longer.&#xD;
&#xD;
         27. Any other reason that would make the subject, in the opinion of the Investigator or&#xD;
             sponsor, unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Applied Research Center of Arkansas Inc.</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T. Joseph Raoff MD Inc. / Encino Research Center</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>91436</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Dermatology Clinical Research</name>
      <address>
        <city>Fremont</city>
        <state>California</state>
        <zip>94538</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Specialist Inc. - Murrieta</name>
      <address>
        <city>Murrieta</city>
        <state>California</state>
        <zip>92562</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rady Childern's Hospital - San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Science Institute</name>
      <address>
        <city>Santa Monica</city>
        <state>California</state>
        <zip>90404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Clinical Research</name>
      <address>
        <city>Davie</city>
        <state>Florida</state>
        <zip>33328</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Troy Sullivan</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DS Research</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40241</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delright Research</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medisearch Clinical Trails</name>
      <address>
        <city>Saint Joseph</city>
        <state>Missouri</state>
        <zip>64506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington Univerisy in St. Louis</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JDR Dermatology Research LLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Acne Treatment and Research Center</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07960</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aventiv Research Inc - Dublin</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Greenville Dermatology, LLC</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermresearch Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Skin Research at Suzanne Bruce &amp; Associates Dermatology</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMAX Clincial Research</name>
      <address>
        <city>Adelaide</city>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>BurwoodDermatology</name>
      <address>
        <city>Burwood</city>
        <zip>6100</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>East Melbourne</city>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Eastern Health Specialists</name>
      <address>
        <city>Hectorville</city>
        <zip>5073</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Specialists PTY LTD</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St George Dermatology &amp; Skin Cancer Center</name>
      <address>
        <city>Kogarah</city>
        <zip>2217</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Captain Stirling Medical Centre</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Hospital</name>
      <address>
        <city>Westmead</city>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Veracity Clinical Research</name>
      <address>
        <city>Woolloongabba</city>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Optilam Clinical Trials</name>
      <address>
        <city>Auckland</city>
        <zip>1010</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials New Zealand LTD</name>
      <address>
        <city>Hamilton</city>
        <zip>3204</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Wellington</city>
        <zip>6021</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>New Zealand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://neweczematrial.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 29, 2019</study_first_submitted>
  <study_first_submitted_qc>January 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">January 31, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CBD</keyword>
  <keyword>Synthetic CBD</keyword>
  <keyword>Cannabidiol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dermatitis, Atopic</mesh_term>
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Eczema</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

